A summary of the test procedures and operational details of a Delaware River and an ocean dumping pollution monitoring experiment conducted 28 August 1975

Two remote sensor evaluation experiments are discussed. One experiment was conducted at the DuPont acid-dump site off the Delaware coast. The second was conducted at an organic waste outfall in the Delaware River. The operational objective of obtaining simultaneous sea truth sampling with remote sensors overpasses was met. Descriptions of the test sites, sensors, sensor platforms, flight lines, sea truth data collected, and operational chronology are presented

Processing of combined domestic bath and laundry waste waters for reuse as commode flushing water

An experimental investigation of processes and system configurations for reclaiming combined bath and laundry waste waters for reuse as commode flush water was conducted. A 90-min recycle flow was effective in removing particulates and in improving other physical characteristics to the extent that the filtered water was subjectively acceptable for reuse. The addition of a charcoal filter resulted in noticeable improvements in color, turbidity, and suds elimination. Heating and chlorination of the waste waters were investigated for reducing total organism counts and eliminating coliform organisms. A temperature of 335.9 K (145 F) for 30 min and chlorine concentrations of 20 mg/l in the collection tank followed by 10 mg/l in the storage tank were determined to be adequate for this purpose. Water volume relationships and energy-use rates for the waste water reuse systems are also discussed

The chemical/physical and microbiological characteristics of typical bath and laundry waste waters

Chemical/physical and microbiological characteristics are studied of typical bath and laundry waters collected during a 12 day test in which the untreated waste waters were reused for toilet flush. Most significant changes were found for ammonia, color, methylene blue active substances, phosphates, sodium, sulfates, total organic carbon, total solids, and turbidity in comparison with tap water baseline. The mean total number of microorganisms detected in the waste waters ranged from 1 million to 10 to the 7th power cells/m1 and the mean number of possible coliforms ranged from 10 to the 5th power to 1 million. An accumulation of particulates and an objectible odor were detected in the tankage used during the 12 day reuse of the untreated waste waters. The combined bath and laundry waste waters from a family of four provided 91 percent of the toilet flush water for the same family

Concepts for manned lunar habitats

The design philosophy that will guide the design of early lunar habitats will be based on a compromise between the desired capabilities of the base and the economics of its development and implantation. Preferred design will be simple, make use of existing technologies, require the least amount of lunar surface preparation, and minimize crew activity. Three concepts for an initial habitat supporting a crew of four for 28 to 30 days are proposed. Two of these are based on using Space Station Freedom structural elements modified for use in a lunar-gravity environment. A third concept is proposed that is based on an earlier technology based on expandable modules. The expandable modules offer significant advantages in launch mass and packaged volume reductions. It appears feasible to design a transport spacecraft lander that, once landed, can serve as a habitat and a stand-off for supporting a regolith environmental shield. A permanent lunar base habitat supporting a crew of twelve for an indefinite period can be evolved by using multiple initial habitats. There appears to be no compelling need for an entirely different structure of larger volume and increased complexity of implantation

Method of providing a lunar habitat from an external tank

A lunar habitat is provided by placing an external tank of an orbiter in a low Earth orbit where the hydrogen tank is separated from the intertank and oxygen tank which form a base structure. The base structure is then outfitted with an air lock, living quarters, a thermal control system, an environmental control and life support system, and a propulsion system. After the mounting of an outer sheath about the base structure to act as a micrometeoroid shield, the base structure is propelled to a soft landing on the moon. The sheath is mounted at a distance from the base structure to provide a space therebetween which is filled with regolith after landing. Conveniently, a space station is used to outfit the base structure. Various elements of the oxygen tank and intertank are used in outfitting

Greywater recycling: Treatment options and applications

Wastewater is an immense resource that could find significant applications in regions of water scarcity. Greywater has particular advantages in that it is a large source with a low organic content. Through critical analysis of data from existing greywater recycling applications, this paper presents a review of existing technologies and applications by collating a disparate information base and comparing/contrasting the strengths and weaknesses of different approaches. Simple technologies and sand filters have been shown to have a limited effect on greywater; membranes are reported to provide good solids removal but cannot efficiently tackle the organic fraction. Alternatively, biological and extensive schemes achieve a good general treatment of greywater with particularly effective removal of organics. The best overall performances were observed within schemes that combine different types of methods to ensure effective treatment of all the fractions

Intravenous Aviptadil and Remdesivir for Treatment of COVID-19-Associated Hypoxaemic Respiratory Failure in the USA (Tesico): A Randomised, Placebo-Controlled Trial

BACKGROUND: There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. METHODS: TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA. Hospitalised adult patients were eligible for the study if they had acute hypoxaemic respiratory failure due to confirmed SARS-CoV-2 infection and were within 4 days of the onset of respiratory failure. Participants could be randomly assigned to both study treatments in a 2 × 2 factorial design or to just one of the agents. Participants were randomly assigned with a web-based application. For each site, randomisation was stratified by disease severity (high-flow nasal oxygen or non-invasive ventilation vs invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]), and four strata were defined by remdesivir and aviptadil eligibility, as follows: (1) eligible for randomisation to aviptadil and remdesivir in the 2 × 2 factorial design; participants were equally randomly assigned (1:1:1:1) to intravenous aviptadil plus remdesivir, aviptadil plus remdesivir matched placebo, aviptadil matched placebo plus remdesvir, or aviptadil placebo plus remdesivir placebo; (2) eligible for randomisation to aviptadil only because remdesivir was started before randomisation; (3) eligible for randomisation to aviptadil only because remdesivir was contraindicated; and (4) eligible for randomisation to remdesivir only because aviptadil was contraindicated. For participants in strata 2-4, randomisation was 1:1 to the active agent or matched placebo. Aviptadil was administered as a daily 12-h infusion for 3 days, targeting 600 pmol/kg on infusion day 1, 1200 pmol/kg on day 2, and 1800 pmol/kg on day 3. Remdesivir was administered as a 200 mg loading dose, followed by 100 mg daily maintenance doses for up to a 10-day total course. For participants assigned to placebo for either agent, matched saline placebo was administered in identical volumes. For both treatment comparisons, the primary outcome, assessed at day 90, was a six-category ordinal outcome: (1) at home (defined as the type of residence before hospitalisation) and off oxygen (recovered) for at least 77 days, (2) at home and off oxygen for 49-76 days, (3) at home and off oxygen for 1-48 days, (4) not hospitalised but either on supplemental oxygen or not at home, (5) hospitalised or in hospice care, or (6) dead. Mortality up to day 90 was a key secondary outcome. The independent data and safety monitoring board recommended stopping the aviptadil trial on May 25, 2022, for futility. On June 9, 2022, the sponsor stopped the trial of remdesivir due to slow enrolment. The trial is registered with ClinicalTrials.gov, NCT04843761. FINDINGS: Between April 21, 2021, and May 24, 2022, we enrolled 473 participants in the study. For the aviptadil comparison, 471 participants were randomly assigned to aviptadil or matched placebo. The modified intention-to-treat population comprised 461 participants who received at least a partial infusion of aviptadil (231 participants) or aviptadil matched placebo (230 participants). For the remdesivir comparison, 87 participants were randomly assigned to remdesivir or matched placebo and all received some infusion of remdesivir (44 participants) or remdesivir matched placebo (43 participants). 85 participants were included in the modified intention-to-treat analyses for both agents (ie, those enrolled in the 2 x 2 factorial). For the aviptadil versus placebo comparison, the median age was 57 years (IQR 46-66), 178 (39%) of 461 participants were female, and 246 (53%) were Black, Hispanic, Asian or other (vs 215 [47%] White participants). 431 (94%) of 461 participants were in an intensive care unit at baseline, with 271 (59%) receiving high-flow nasal oxygen or non-invasive ventiliation, 185 (40%) receiving invasive mechanical ventilation, and five (1%) receiving ECMO. The odds ratio (OR) for being in a better category of the primary efficacy endpoint for aviptadil versus placebo at day 90, from a model stratified by baseline disease severity, was 1·11 (95% CI 0·80-1·55; p=0·54). Up to day 90, 86 participants in the aviptadil group and 83 in the placebo group died. The cumulative percentage who died up to day 90 was 38% in the aviptadil group and 36% in the placebo group (hazard ratio 1·04, 95% CI 0·77-1·41; p=0·78). The primary safety outcome of death, serious adverse events, organ failure, serious infection, or grade 3 or 4 adverse events up to day 5 occurred in 146 (63%) of 231 patients in the aviptadil group compared with 129 (56%) of 230 participants in the placebo group (OR 1·40, 95% CI 0·94-2·08; p=0·10). INTERPRETATION: Among patients with COVID-19-associated acute hypoxaemic respiratory failure, aviptadil did not significantly improve clinical outcomes up to day 90 when compared with placebo. The smaller than planned sample size for the remdesivir trial did not permit definitive conclusions regarding safety or efficacy. FUNDING: National Institutes of Health

Strategies to improve first attempt success at intubation in critically ill patients

Tracheal intubation in critically ill patients is a high-risk procedure. The risk of complications increases with repeated or prolonged attempts, making expedient first attempt success the goal for airway management in these patients. Patient-related factors often make visualization of the airway and placement of the tracheal tube difficult. Physiologic derangements reduce the patient's tolerance for repeated or prolonged attempts at laryngoscopy and, as a result, hypoxaemia and haemodynamic deterioration are common complications. Operator-related factors such as experience, device selection, and pharmacologic choices affect the odds of a successful intubation on the first attempt. This review will discuss the 'difficult airway' in critically ill patients and highlight recent advances in airway management that have been shown to improve first attempt success and decrease adverse events associated with the intubation of critically ill patients.Published 24 May 2016; 12 month embargo.This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Preparation of Small Well Characterized Plutonium Oxide Reference Materials and Demonstration of the Usefulness of Such Materials for Nondestructive Analysis

Calibration of neutron coincidence and multiplicity counters for passive nondestructive analysis (NDA) of plutonium requires knowledge of the detector efficiency parameters. These are most often determined empirically. Bias from multiplication and unknown impurities may be incurred even with small plutonium metal samples. Five sets of small, pure plutonium metal standards prepared with well-known geometry and very low levels of impurities now contribute to determining accurate multiplication corrections. Recent measurements of these metal standards, with small but well-defined multiplication and negligible yield of other than fission neutrons, demonstrate an improved characterization and calibration of neutron coincidence/multiplicity counters. The precise knowledge of the mass and isotopic composition of each standard also contributes significantly to verifying the accuracy of the most precise calorimetry and gamma-ray spectroscopy measurements